Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANORINAL vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LANORINAL is a combination product containing acetaminophen, which inhibits cyclooxygenase (COX) enzymes and modulates cannabinoid receptors via its metabolite AM404; and butalbital, a barbiturate that enhances GABA-A receptor activity, producing sedative and anxiolytic effects.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Relief of tension-type headache,Relief of muscle contraction headache
Hypertension
1-2 mg intravenously or intramuscularly every 2-4 hours as needed for pain.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in hepatic impairment.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Acetaminophen is primarily metabolized by glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3); a minor pathway via CYP2E1 produces the toxic metabolite NAPQI. Butalbital is metabolized primarily by hydroxylation via CYP2C19.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 30-50% unchanged; fecal/biliary: 50-70% as metabolites.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
99% bound, primarily to albumin.
~90%, primarily to albumin
0.15-0.25 L/kg, indicating limited extravascular distribution.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 70-85%.
Oral: 50–60% (extensive first-pass metabolism)
GFR 30-50 m L/min: administer 75% of normal dose. GFR 10-29 m L/min: administer 50% of normal dose. GFR <10 m L/min: use not recommended.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
0.02-0.05 mg/kg intravenously or intramuscularly every 4-6 hours as needed; maximum single dose 2 mg.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at 0.5-1 mg intravenously or intramuscularly; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Hepatotoxicity is often associated with use of acetaminophen in doses exceeding 4000 mg per day and often involves more than one acetaminophen-containing product.
None
Risk of hepatotoxicity with high doses or chronic use of acetaminophen; hypersensitivity reactions including anaphylaxis; risk of CNS depression and respiratory depression with butalbital; potential for abuse, dependence, and withdrawal; interactions with alcohol and other CNS depressants; use with caution in patients with hepatic or renal impairment.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to acetaminophen, butalbital, or any component; severe hepatic impairment; porphyria; history of addiction to barbiturates; concomitant use with other barbiturates or potent CNS depressants (relative).
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-fiber foods that may reduce absorption; separate by 1 hour. Limit foods high in potassium (e.g., bananas, oranges) unless advised. Avoid herbal supplements like St. John's Wort and hawthorn.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
LANORINAL (digoxin) is FDA pregnancy category C. First trimester: No well-controlled studies; animal studies show fetal toxicity at high doses. Second and third trimesters: No increased risk of major malformations with therapeutic doses; monitor for fetal bradycardia and digoxin toxicity due to increased maternal clearance. Risk of preterm labor and low birth weight from underlying maternal condition (e.g., heart failure).
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Digoxin is excreted into breast milk with a milk-to-plasma (M/P) ratio of 0.8–0.9. The relative infant dose is approximately 1–5% of the maternal weight-adjusted dose, generally considered compatible with breastfeeding. Monitor infant for bradycardia and signs of digoxin toxicity (vomiting, arrhythmias).
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Pregnancy increases digoxin clearance by 30–50%, particularly in the third trimester. Doses may need to be increased by 30–50% to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels within 2 weeks, requiring dose reduction. Monitor serum digoxin levels every 1–2 months and adjust dose accordingly.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Monitor digoxin levels closely due to narrow therapeutic index. Adjust dose in renal impairment. Check potassium and magnesium levels to avoid arrhythmias. Use with caution in elderly and patients with hypothyroidism.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not skip or double doses.,Report symptoms of toxicity: nausea, vomiting, blurred vision, irregular heartbeat.,Avoid taking with other heart medications unless directed by your doctor.,Maintain a consistent diet regarding potassium intake; avoid licorice.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANORINAL vs ALDORIL 15, answered by our medical review team.
LANORINAL is a Antihypertensive that works by LANORINAL is a combination product containing acetaminophen, which inhibits cyclooxygenase (COX) enzymes and modulates cannabinoid receptors via its metabolite AM404; and butalbital, a barbiturate that enhances GABA-A receptor activity, producing sedative and anxiolytic effects.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANORINAL and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANORINAL is: 1-2 mg intravenously or intramuscularly every 2-4 hours as needed for pain.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANORINAL and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANORINAL is classified as Category C. LANORINAL (digoxin) is FDA pregnancy category C. First trimester: No well-controlled studies; animal studies show fetal toxicity at high doses. Second and third trimesters: No incr. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.